Retatrutide 20mg Research Peptide - Precision Chain Peptides

Retatrutide 20mg Research Peptide - Precision Chain Peptides

£59.99 + FREE shipping on all orders over £200

Availability: In stock

For Research Use Only

Eli Lilly’s latest development, Retatrutide, is showing extraordinary potential as a groundbreaking treatment for obesity and metabolic health. On 21 May 2026, Lilly published the long-awaited topline results from the TRIUMPH-1 Phase 3 trial, and the data is striking: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks, with 45.3% of patients losing 30% or more — a threshold previously only achievable with bariatric surgery.

Unlike other weight loss injections, Retatrutide works by targeting three key hormone pathways rather than one or two, offering enhanced effectiveness. Phase 3 clinical trials have now demonstrated weight loss results that surpass anything previously seen in this drug class, positioning Retatrutide as a potentially transformative alternative to existing treatments.